Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections

Area of Science:

• Infectious Diseases
• Antimicrobial Resistance
• Clinical Pharmacology

Background:

• Multidrug-resistant (MDR) infections pose a significant global health threat.
• Pseudomonas aeruginosa is a common cause of difficult-to-treat hospital-acquired infections.
• Novel antibiotic combinations are crucial for combating resistant bacterial strains.

Purpose of the Study:

• To assess the clinical outcomes of imipenem-cilastatin-relebactam in patients with serious infections.
• To evaluate the efficacy of this combination against multidrug-resistant Pseudomonas aeruginosa.

Main Methods:

• A multicenter case series involving 21 patients treated with imipenem-cilastatin-relebactam.
• Analysis of infection sources, primary pathogens, and antimicrobial susceptibility.
• Evaluation of 30-day survival and adverse events.

Main Results:

• Pulmonary infections were the most common source (52%).
• Pseudomonas aeruginosa was the primary pathogen (76%), with 94% of isolates being multidrug-resistant.
• Thirty-day survival was observed in 67% of patients (14/21).
• Two patients experienced adverse effects.

Conclusions:

• Imipenem-cilastatin-relebactam demonstrated potential in treating complex infections caused by multidrug-resistant pathogens.
• Further investigation is warranted to establish its role in clinical practice.
• The safety profile appears manageable in this case series.